Podcast Episodes
Back to Search
Biotech’s New Cycle, JPM Deal Hype and Where Alpha Still Hides
In this episode of Denatured, Jennifer C. Smith-Parker speaks with RTW’s Rod Wong and Stephanie Sirota how shifting JPM deal timing masks record M&A …
5 months, 1 week ago
Roche Makes Obesity Splash, Moderna Cans Vaccine Trials, Sarepta’s New Data, More
Roche made the biggest splash this week so far, announcing on Tuesday that GLP-1/GIP injectable CT-388 led to 22.5%weight loss in a Phase II trial. T…
5 months, 1 week ago
From Sound Bites to Signals: Editors Parse Executive and Investor Chatter at JPM
In this episode of Denatured, BioSpace editorial team members, Senior Editor, Annalee Armstrong, and News Editor, Dan Samorodnitsky, discuss their po…
5 months, 2 weeks ago
JPM26 Recap, Novo’s Oral Wegovy Soars as Lilly’s Orforglipron Is Delayed, IPOs Return
The 2026 J.P. Morgan Healthcare Conference concludedlast week without a big M&A deal. But the meeting was anything but boring, with President Donald …
5 months, 2 weeks ago
Bonus: Q4 2025 Job Market Update
In this episode, BioSpace’s Vice President of Marketing Chantal Dresner and Careers Editor Angela Gabriel discuss Q4 2025 job market performance, sha…
5 months, 3 weeks ago
Deals Roll at JPM26, Policy Front and Center, IPOs Are Back, FDA Stays Busy
AbbVie bet nearly $5 billion for the ex-China rights to RemeGen’s PD-1/VEGF bispecific and Novartis struck a $1.5 billion Alzheimer’s-focused deal wi…
5 months, 3 weeks ago
From Nuclear Winter to Renewal: Biotech Investing for 2026
In this episode of Denatured, Jennifer C. Smith-Parker speaks to Maha Katabi, general partner at Sofinnova Investments and Andrew Lam, managing direc…
6 months ago
Novo Launches Oral Obesity Pill, Lilly Targets Lofty Revenue, FDA and M&A in Focus
Obesity titans Novo Nordisk and Eli Lilly characteristically kicked off 2026 in the headlines. After capping 2025 with the first-ever FDA approval of…
6 months ago
Inside the 2026 Biotech Landscape: Innovation, Investment and Global Momentum
In this episode of Denatured, Jennifer Smith-Parker speaks to Kenneth Galbraith, CEO at Zymeworks and Josh Smiley, president and COO at Zai Lab, abou…
6 months, 3 weeks ago
Lilly’s Triple Triumph, Prasad’s COVID Error, J&J’s Surprise Voucher, M&A Targets
Eli Lilly is wrapping up 2025 with record-breaking weight loss in a late-stage trial for its triple hormone receptor agonist retatrutide. Results fro…
6 months, 3 weeks ago